Teva Reinforces Leadership Position in CNS with Acquisition of Auspex
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall St slides after strong jobs report bolsters hawkish Fed bets
- US nonfarm payrolls surge in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil slides on Friday, heads for weekly gain on US-Iran fight
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Teva Pharma (TEVA) 'Transformational' Deal Still Possible Following Auspex, Jefferies Says
March 31, 2015 8:27 AM EDTJefferies analyst David Steinberg reiterated a Buy rating and $66 price target on Teva Pharma (NYSE: TEVA) after the company entered into a definitive agreement to acquire Auspex (ASPX) for $3.2B. The analyst continues to believe that a large "transformational" acquisition is still a... More
William Blair Downgrades Auspex Pharmaceuticals (ASPX) to Market Perform
March 31, 2015 7:09 AM EDTWilliam Blair downgraded Auspex Pharmaceuticals (NASDAQ: ASPX) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Auspex Pharmaceuticals click here. For more ratings news on Auspex Pharmaceuticals click here.
Shares of Auspex Pharmaceuticals closed at $100.36 yesterday.
... MoreStifel Downgrades Auspex Pharmaceuticals (ASPX) to Hold
March 31, 2015 7:07 AM EDTStifel downgraded Auspex Pharmaceuticals (NASDAQ: ASPX) from Buy to Hold.
For an analyst ratings summary and ratings history on Auspex Pharmaceuticals click here. For more ratings news on Auspex Pharmaceuticals click here.
Shares of Auspex Pharmaceuticals closed at $100.36 yesterday.
... MoreBaird Downgrades Auspex Pharmaceuticals (ASPX) to Neutral
March 31, 2015 7:06 AM EDTBaird downgraded Auspex Pharmaceuticals (NASDAQ: ASPX) from Outperform to Neutral.
For an analyst ratings summary and ratings history on Auspex Pharmaceuticals click here. For more ratings news on Auspex Pharmaceuticals click here.
Shares of Auspex Pharmaceuticals closed at $100.36 yesterday.
... MoreOppenheimer Upgrades Teva Pharma (TEVA) to Outperform
March 31, 2015 6:48 AM EDTOppenheimer upgraded Teva Pharma (NYSE: TEVA) from Perform to Outperform with a price target of $77.00.
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $62.52 yesterday.
... MoreTeva Pharma (TEVA) Price Target Raised to $68 at Deutsche Bank; Large & Small Deals Remain Priority, Notes Analyst
March 30, 2015 1:59 PM EDTDeutsche Bank maintained a Buy rating on Teva Pharma (NYSE: TEVA) and raised is price target to $68.00 (from $67.00). Earlier Teva announced a deal to acquire Auspex Pharmaceuticals (NASDAQ: ASPX). Analyst Gregg Gilbert pointed out that this... More
BMO Capital Downgrades Auspex Pharmaceuticals (ASPX) to Market Perform on Takeover
March 30, 2015 11:57 AM EDTBMO Capital downgraded Auspex Pharmaceuticals (NASDAQ: ASPX) from Outperform to Market Perform after the company agreed to be acquired by Teva Pharmaceuticals this morning.
For an analyst ratings summary and ratings history on Auspex Pharmaceuticals... More
Piper Jaffray Downgrades Auspex Pharmaceuticals (ASPX) to Neutral
March 30, 2015 11:08 AM EDTPiper Jaffray downgraded Auspex Pharmaceuticals (NASDAQ: ASPX) from Overweight to Neutral.
For an analyst ratings summary and ratings history on Auspex Pharmaceuticals click here. For more ratings news on Auspex Pharmaceuticals click here.
Shares of Auspex Pharmaceuticals closed at $70.91 yesterday.
... MoreTeva Pharma (TEVA) to Acquire Auspex Pharma (ASPX) in $3.2B Deal
March 30, 2015 7:02 AM EDTTeva Pharma (NYSE: TEVA) and Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), today announced that they have entered into a definitive merger agreement under which Teva will commence a tender offer for all of the outstanding shares of Auspex at $101.00 per share in cash, representing total consideration of approximately $3.2 billion in enterprise value and approximately $3.5 billion in equity value. This transaction is expected to enhance Tevas revenue and earnings growth profile and strengthen its core central nervous system (CNS) franchise with the addition of Auspexs portfolio of innovative... More
